Gravar-mail: TRTH-22. DEVELOPING RISK-BASED SELECTION CRITERIA FOR THE NEXT SIOP TRIAL OF “SIGHT-SAVING THERAPY” FOR CHILDREN WITH NF1-ASSOCIATED VISUAL PATHWAY GLIOMA (NF1-VPG) – A QUALITATIVE ANALYSIS OF A CONSENSUS SURVEY